News and Trends 10 Feb 2023 Heartseed and Novo Nordisk dose first patient in heart failure cell therapy study Heartseed Inc. and Novo Nordisk A/S say Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated four-week data on the patient, who lives with advanced heart failure and has given approval for […] February 10, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Feb 2023 Possible drug targets from Korean atherosclerosis research Research suggests that the enzyme phosphoenolpyruvate carboxykinase 2 (PCK2) and its gene play a role in the development of vascular injury and atherosclerosis. Atherosclerosis is a deadly disease; research suggests that proliferation of vascular smooth muscle cells (VSMCs) and formation of a neointimal layer along the inner lining of arteries play a major role in […] February 2, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jan 2023 Ubiquigent and University of Glasgow to collaborate on drug discovery Ubiquigent Limited, a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a DUB implicated in neruodegenerative, renal, and cardiovascular diseases. Overseen by structural biology experts […] January 24, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 10 Jan 2023 Innovative biomaterials are revolutionizing tissue regeneration Scientists are increasingly realizing the potential of biomaterials to help with many tasks. A key area biomaterials are being used in is tissue engineering and regeneration, something several biotechs and academic labs are currently exploring. Biomaterials are materials or substances designed to function in a biological environment, which may or may not be made of […] January 10, 2023 - 14 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 15 Dec 2022 Cell reprogramming can reverse fibrosis after heart attack Researchers in Japan may have found a way to repair cardiac damage in patients suffering from chronic heart attack and heart failure. In a study published in Circulation, researchers from the University of Tsukuba have revealed that changing heart cell programming by tweaking the expression of a few key genes can actually reverse the lasting […] December 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 Fallouh Healthcare’s device to give early diagnosis for post-surgery strangulation risk U.K.-based Fallouh Healthcare is developing a device to monitor cardiac patients after surgery, which is when a condition, called cardiac tamponade, can strike. The company says patients recovering from heart surgery can be at risk from the life-threatening condition that sees fluid build-up around the heart, strangling its ability to beat properly. Fallouh Healthcare, formed […] December 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 Trial to start for new heart attack drug A potential new drug to improve the long-term outcomes for heart attack patients will be trialed in the U.K. With the signing of a partnership between the University of Birmingham and Acticor Biotech, a new clinical trial called LIBERATE will take place in two acute care hospitals in the U.K.: the Queen Elizabeth Hospital, Birmingham […] November 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 18 Nov 2022 How cardioids can usher in the next generation of drug discovery The California-based Molecular Devices brings automated 3D cell culture and image analysis together with HeartBeat.bio’s cardioid technology to enable unique and scalable drug discovery and cardiac safety testing. Cardiovascular diseases are the leading cause of death worldwide, claiming an estimated 17.9 million lives each year. Despite this, the cardiovascular therapeutics market has lagged behind the […] November 18, 2022 - 6 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
More News! 15 Nov 2022 Sequana Medical has positive results for heart failure therapy drug Sequana Medical has had some very positive top-line results from a phase 2a study, that the company says reinforces its view that direct sodium removal (DSR) is a potential disease modifying heart failure therapy. The study called SAHARA was testing its first-generation DSR product, DSR 1.0. Data from ten evaluable diuretic-resistant heart failure patients with […] November 15, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2022 Proteins identified by FunSel and developed by Forcefield can preserve heart function Forcefield Therapeutics, has presented positive preclinical data on three proteins identified by it FunSel platform that have the potential to preserve heart function following a heart attack. The company that works with therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction infarction. The paper, Novel Recombinant Cardioprotective Factors Against Myocardial […] November 7, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 11 Oct 2022 The biggest private biotech investments in September 2022 The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022, with insect protein and cell therapies attracting big funding rounds. Autumn is in full swing in the Northern Hemisphere. After a breather in August 2022, September saw the return of big fundraising activity for biotech companies. We’ve gathered the biggest […] October 11, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2022 Novartis Biome UK Heart Health Catalyst 2022 winners announced Novartis Pharmaceuticals UK has announced that Xim, creators of Lifelight, and PocDoc are the successful companies of the Novartis Biome UK Heart Health Catalyst 2022, in partnership with Medtronic, RYSE Asset Management, Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+. Lifelight and PocDoc will receive support to scale their innovative digital […] October 6, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email